- Home
- LLY
as 11-20-2024 4:00pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 778.3B | IPO Year: | N/A |
| Target Price: | $962.05 | AVG Volume (30 days): | 5.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 22 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 9.25 | EPS Growth: | 67.52 |
| 52 Week Low/High: | $561.65 - $972.53 | Next Earning Date: | 10-30-2024 |
| Revenue: | $40,863,300,000 | Revenue Growth: | 27.41% |
| Revenue Growth (this year): | 34.95% | Revenue Growth (next year): | 28.68% |
Stock Insider Trading Activity of Eli Lilly and Company (LLY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LILLY ENDOWMENT INC | LLY | 10% Owner | Sep 3 '24 | Sell | $967.74 | 24,084 | $23,281,840.23 | 96,891,978 | |
| LILLY ENDOWMENT INC | LLY | 10% Owner | Aug 27 '24 | Sell | $969.44 | 24,552 | $23,777,667.73 | 96,891,978 | |
| Zakrowski Donald A | LLY | SVP, Finance, & CAO | Aug 26 '24 | Sell | $950.00 | 750 | $712,500.00 | 6,380 |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Barrons.com
3 hours ago
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Insider Monkey
11 hours ago
Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
Quartz
18 hours ago
Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Reuters
19 hours ago
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Investor's Business Daily
21 hours ago
Eli Lilly Option Trade Produces $1,125, If You Can Tolerate The Heavy Risk
MT Newswires
a day ago
Eli Lilly Advances ALS Drug Targets With Verge Genomics Collaboration
Motley Fool
a day ago
Is It Time to Sell Eli Lilly and Pfizer Stocks?
GlobeNewswire
a day ago
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.